REPL replimune.com: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

The EV/EBITDA price chart for Replimune Group, Inc. (REPL) on the GURU.Markets platform is currently at 0.00. Replimune Group, Inc. (REPL) develops anti-tumor agents while adhering to strict environmental standards and bioethics. Business growth relies on partnerships with pharma behemoths for clinical trials; however, the high probability of clinical failure creates significant risks for invested capital.

Replimune Corp - Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan REPL (periode 23.11.2025 - 10.11.2026)

Ringkesan rincian data analitis replimune.com (REPL)

- rega saham lan target rega konsensus:

Kutipan saham Replimune Corp|REPL - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Replimune Inc.|REPL - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Replimune|REPL - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku replimune.com|REPL - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas Replimune Group, Inc.|REPL - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Replimune|REPL - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Replimune Inc.|REPL - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Replimune|Indikator likuiditas cepet replimune.com

- rincian asil keuangan lan kelipatan valuasi:

REPL - Bathi resik taunan|Bathi mangsa ngarep Replimune Group, Inc.|REPL - Rasio rega pasar marang bathi resik|Pangali Forward P/E Replimune Group, Inc.|REPL - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Replimune Inc.|REPL - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Replimune|REPL - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan replimune.com|REPL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Replimune Group, Inc.

Analisis fundamental perusahaan:REPL (Replimune Corp)

For Replimune Group, Inc. (REPL), whose success depends on the outcomes of vaccine clinical trials, the EV/EBITDA multiple serves as a tool for valuing the business relative to its operating profit. This metric aggregates market capitalization and net debt, comparing them against earnings before depreciation and amortization. By analyzing the historical EV/EBITDA value, an investor can see the current level of 0.00, which reflects market expectations. This allows for an assessment of the company's resilience regardless of macroeconomic cycles.

Analisis pesaing Replimune Group, Inc.